Page 2 - Head External Communications Editorial Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } }); Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee ·       With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee.    ·       MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief.     Aachen, Germany, 12 April 2021 – Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of

Nordrhein westfalenUnited statesFabia kehrenGabriel baertschiJan adamsGrunenthal groupNational institute of arthritisHead external communications editorial managementTransient receptor potential vanilloidLatin americaSkin diseasesWhat causes osteoarthritisHead external communicationsனோற்ர்ேன் வெஸ்ட்ஃபாலன்ஒன்றுபட்டது மாநிலங்களில்ஜான் ஆடம்ஸ்